A curated roundup of published scientific studies from PubMed and PMC, organized by research area — no hype, just evidence.
Produced by bees that pollinate the native Leptospermum scoparium (mānuka) tree in New Zealand and parts of Australia, this honey has a distinct biochemical profile not found in other honey varieties.
Its potency is measured using the Unique Manuka Factor (UMF) and Methylglyoxal (MGO) rating systems, which quantify its core antibacterial compounds. Medical-grade versions have been FDA-cleared for wound management.
The primary antibacterial compound unique to mānuka honey. Disrupts bacterial cell membranes and inhibits DNA synthesis. Levels range from ~30 mg/kg (low grade) to 800+ mg/kg (high grade).
A marker compound unique to L. scoparium nectar, used to authenticate genuine mānuka honey and distinguish it from imitations.
Antioxidant compounds including luteolin, kaempferol, and quercetin that contribute to anti-inflammatory and potential anti-cancer activity.
A synergistic compound shown in 2023 research to enhance MGO's antibacterial effectiveness, especially at concentrations above 500 mg/kg.
Filter by research area. Each card links directly to the source publication.
A retrospective study of patients with chronic discharging wounds found that mānuka honey dressings promoted healing and reduced infection. Authors concluded it is a "promising" material for wound management in cases where conventional treatments stall.
View on PubMedA direct laboratory comparison of three commercial wound products — collagen sheet, mānuka honey sheet, and a novel bioengineered combination — found mānuka honey drove significant reduction in inflammatory markers and strong growth factor production relevant to tissue repair.
View on PubMedUniversity of Memphis researchers demonstrated that mānuka honey reduces NETosis (a form of immune-driven cell death that can impair wound closure) when applied to bioengineered scaffolds. The study helped explain one mechanism by which mānuka honey supports tissue regeneration.
View on PMCTested UMF 5+, 10+, and 15+ mānuka honey against 128 clinical wound isolates — including gram-positive, gram-negative, drug-susceptible, and multidrug-resistant (MDR) organisms. Higher UMF grades generally produced lower minimum inhibitory concentrations (MICs), confirming the rating system as a practical guide to antibacterial strength.
View on PubMedCombining mānuka honey (Medihoney) with rifampicin showed synergistic inhibition of MRSA and clinical S. aureus isolates using checkerboard assays, time-kill curves, and agar diffusion. Critically, the combination also prevented the emergence of rifampicin-resistant strains — suggesting honey may help counter antibiotic resistance development.
View on PMCThis study revealed that mānuka honey's bacteriostatic activity cannot be fully explained by MGO alone. Concentrations of 3-phenyllactic acid (3-PLA) above 500 mg/kg synergistically enhance MGO's effect against Bacillus subtilis, pointing to a multi-compound mechanism of action in genuine mānuka honey.
View on PubMedTested mānuka honey against MDR and XDR strains of Salmonella Typhi causing septicemia. Most strains were inhibited at just 3.125% v/v concentration and killed at 6.25% v/v — promising results for a pathogen increasingly resistant to conventional antibiotics.
View on PubMedUCLA researchers at the Jonsson Comprehensive Cancer Center found dose-dependent inhibition of MCF-7 breast cancer cell proliferation at 0.3–5.0% w/v. Mānuka honey triggered significant apoptosis in cancer cells while leaving non-malignant human mammary epithelial cells largely unaffected at comparable concentrations.
View on PubMedMānuka honey combined with 5-fluorouracil (5-FU), a standard colorectal cancer drug, induced oxidative stress and apoptosis, altered metabolic phenotypes, and suppressed metastatic ability in colon cancer cell lines — performing better than 5-FU alone. Results suggest a potential role as a chemo-sensitizer.
View on PubMedIdentified a novel mechanism by which mānuka honey induces cancer cell death: disruption of intracellular calcium balance and reactive oxygen species homeostasis via Aquaporin-3 channels. Mānuka honey produced a stronger cytotoxic effect than acacia or buckwheat honey, and induced apoptosis in A431 cancer cells within just 3 hours of treatment.
View on PubMedTested commercially available mānuka honey for total polyphenol content and DPPH radical scavenging capacity, then evaluated its ability to protect human fibroblasts from UV-induced oxidative stress. Results showed honey significantly interfered with cell metabolism; MGO content alone had only a minor impact on oxidative protection, underscoring the role of polyphenols.
View on PubMedA 3-arm, double-blind RCT enrolled 75 adults with functional dyspepsia (chronic indigestion). Participants consumed Lepteridine-standardized mānuka honey (10g twice daily) for 6 weeks. The study investigated symptom severity, quality of life, bowel movement outcomes, and appearance of mānuka-derived metabolites in blood and urine. Full results pending publication.
View on PubMedA randomized controlled trial at the British University in Egypt assessed mānuka honey as an oral rinse in elderly patients with xerostomia (dry mouth). Researchers cited mānuka honey's anti-inflammatory properties as the rationale for the intervention; results are available in the full PMC article.
View on PMC30 volunteers chewed UMF 15+ mānuka honey "leather" three times daily for 21 days after meals. Compared to sugarless gum controls, mānuka honey significantly reduced plaque scores and gingival bleeding — despite being a sugar-based product — due to its antimicrobial inhibition of Porphyromonas gingivalis and other oral pathogens.
View on ResearchGateThe UMF™ system is licensed by the UMF Honey Association (New Zealand). Higher grades = higher MGO concentration and potency.
| UMF Grade | MGO (approx.) | Research Application |
|---|---|---|
| UMF 5+ | ~83 mg/kg | General wellness, immune support, daily use |
| UMF 10+ | ~263 mg/kg | Oral health studies, digestive support, minor wounds |
| UMF 15+ | ~514 mg/kg | Gingivitis pilot study grade; moderate antibacterial activity |
| UMF 20+ | ~829 mg/kg | Chronic wound management; strong MRSA inhibition |
| UMF 25+ | ~1200+ mg/kg | Medical-grade; used in clinical dressings and hospital settings |